Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, open-label phase II study to compare the safety and efficacy of lapatinib plus trastuzumab or lapatinib plus capecitabine in trastuzumab-resistant HER2-overexpressing metastatic breast cancer.

Next Previous
X
Search
Trial Profile

Randomised, open-label phase II study to compare the safety and efficacy of lapatinib plus trastuzumab or lapatinib plus capecitabine in trastuzumab-resistant HER2-overexpressing metastatic breast cancer.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms THOR

    • Most Recent Events

    • 07 Aug 2021 Status changed from withdrawn prior to enrolment to discontinued.(End date:2015-06-01).
    • 13 Jan 2016 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 17 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top